BridgeBio Pharma reports first-quarter earnings after the market close Thursday, with investors focused on the commercial trajectory of Attruby, the company’s recently launched heart drug that faces a newly clarified competitive landscape.
Analysts expect a loss of 68 cents per share on revenue of $178.2 million, which would mark substantial improvement from the prior quarter’s results. In February, BridgeBio reported fourth-quarter revenue of $154.2 million that beat expectations, but posted a loss of $1.00 per share, significantly wider than the 72-cent loss analysts had forecast.
The expected sequential revenue gain of roughly 16% reflects the ongoing launch of Attruby, approved in November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and progressive heart condition. Yet profitability expectations have dimmed: EPS estimates have declined 23% over the past 60 days, even as revenue estimates have held largely steady.